27 February 2020 
EMA/CHMP/89174/2020  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Otezla 
apremilast 
On 27 February 2020, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Otezla. The marketing authorisation holder for this medicinal product is Amgen Europe B.V. 
The CHMP adopted a new indication as follows: 
“Behçet’s disease 
Otezla is indicated for the treatment of adult patients with oral ulcers associated with Behçet’s 
disease (BD) who are candidates for systemic therapy.” 
For information, the full indications for Otezla will be as follows: 
“Psoriatic arthritis 
Otezla, alone or in combination with Disease Modifying Antirheumatic Drugs (DMARDs), is 
indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an 
inadequate response or who have been intolerant to a prior DMARD therapy (see section 5.1). 
Psoriasis 
Otezla is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult 
patients who failed to respond to or who have a contraindication to, or are intolerant to other 
systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet-A light 
(PUVA). 
Behçet’s disease 
Otezla is indicated for the treatment of adult patients with oral ulcers associated with Behçet’s 
disease (BD) who are candidates for systemic therapy.” 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
Otezla  
EMA/CHMP/89174/2020 
Page 2/2 
 
  
  
